Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - VALEANT PHARMACEUTICALS INTERNATIONAL | Financial_Report.xls |
| 10-Q - FORM 10-Q - VALEANT PHARMACEUTICALS INTERNATIONAL | a56182e10vq.htm |
| EX-32 - EX-32 - VALEANT PHARMACEUTICALS INTERNATIONAL | a56182exv32.htm |
| EX-15.1 - EX-15.1 - VALEANT PHARMACEUTICALS INTERNATIONAL | a56182exv15w1.htm |
| EX-31.2 - EX-31.2 - VALEANT PHARMACEUTICALS INTERNATIONAL | a56182exv31w2.htm |
| EX-31.1 - EX-31.1 - VALEANT PHARMACEUTICALS INTERNATIONAL | a56182exv31w1.htm |
Exhibit 15.2
August 3 , 2010
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Commissioners:
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Commissioners:
We
are aware that our report dated August 3, 2010 on our review of interim financial
information of Valeant Pharmaceuticals International (the “Company”) for the three-month and
six-month periods ended June 30, 2010 and 2009 and included in the Company’s quarterly report on
Form 10-Q for the quarter ended June 30, 2010 is incorporated by reference in its Registration
Statements on Form S-3 (File No. 333-112904) and Form S-8 (File Nos. 33-56971, 333-81383,
333-73098, 333-85572, 333-109877, 333-109879, 333-142651, 333-156931
and 333-160393) and in Biovail Corp’s Registration Statement on Form S-4 (File No. 333-168254).
Very truly yours,
/s/ PricewaterhouseCoopers LLP